Post-induction, 181 (25%), 146 (21%), and 206 (30%) BCP-ALL patients were classified as standard-risk (SR), intermediate-risk (IR) and high-risk (HR) respectively. This evidence concerns the gene OPN1SW and acute lymphoblastic leukemia.